SCHEMBL4649927

SCHEMBL4649927

O=C(CC1CCNCC1)N1CCC(O)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.48
ITGA2B P08514 2/20 0.48
SMYD3 Q9H7B4 8/20 0.46
GNAI3 P08754 4/20 0.46
GNAO1 P09471 4/20 0.46
GNAI1 P63096 4/20 0.46
NAMPT P43490 1/20 0.42
KDM1A O60341 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
TPSAB1 Q15661 1/20 0.40
TPSD1 Q9BZJ3 1/20 0.40
TPSG1 Q9NRR2 1/20 0.40
SLC6A1 P30531 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRB2 P47870 1/20 0.39
SLC6A12 P48065 1/20 0.39
SLC6A11 P48066 1/20 0.39
SLC6A13 Q9NSD5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11496439 0.87 DDB1 (0.51) ITGB3ITGA2BSMYD3GNAI3GNAO1
SCHEMBL13812236 0.85 ITGB3 (0.46) ITGB3ITGA2BSMYD3GNAI3GNAO1
SCHEMBL16083491 0.84 ALDH1A1 (0.53) ITGB3ITGA2BSMYD3GNAI3GNAO1
SCHEMBL29765411 0.84 KDM1A (0.48) ITGB3ITGA2BSMYD3GNAI3GNAO1
SCHEMBL30364152 0.84 CA2 (0.47) ITGB3ITGA2BSMYD3GNAI3GNAO1
SCHEMBL24026487 0.83 ITGB3 (0.46) ITGB3ITGA2BSMYD3GNAI3GNAO1
SCHEMBL19884747 0.83 GNAI3 (0.54) ITGB3ITGA2BSMYD3GNAI3GNAO1
SCHEMBL16207650 0.81 DDB1 (0.53) ITGB3ITGA2BSMYD3GNAI3GNAO1
SCHEMBL4191524 0.81 SMYD3 (0.45) ITGB3ITGA2BSMYD3GNAI3GNAO1
SCHEMBL3995226 0.81 NAMPT (0.45) ITGB3ITGA2BSMYD3GNAI3GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400511-B1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI YAKUHIN KOGYO KK (JP) 2008-09-03 EP claimed
US-6900326-B2 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2005-05-31 US claimed
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2004-04-01 US claimed
EP-1400511-A1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI KOGYO CO., LTD. (JP) 2004-03-24 EP claimed
CN-111868030-B 1- (1-Tert-butoxycarbonyl-4-piperidylacetyl) -4-methanesulfonyloxy piperidine and preparation method thereof 有机合成药品工业株式会社 2024-07-19 CN disclosed
US-11827603-B2 Method for preparing 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine and 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine YUKI GOSEI KOGYO CO., LTD. (JP) 2023-11-28 US disclosed
US-20220388959-A1 METHOD FOR PRODUCING 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4- MESYLOXYPIPERIDINE AND 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE YUKI GOSEI KOGYO CO., LTD. (JP) 2022-12-08 US disclosed
EP-3741743-A1 METHOD FOR PRODUCING 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE AND 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE Yuki Gosei Kogyo Co., Ltd. (JP) 2020-11-25 EP disclosed
CN-111868030-A Preparation method of 1- (1-tert-butyloxycarbonyl-4-piperidylacetyl) -4-methylsulfonyloxypiperidine and 1- (1-tert-butyloxycarbonyl-4-piperidylacetyl) -4-methylsulfonyloxypiperidine 有机合成药品工业株式会社 2020-10-30 CN disclosed
WO-2019142901-A1 METHOD FOR PRODUCING 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE AND 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE 有機合成薬品工業株式会社 2019-07-25 WO disclosed
EP-1400511-B1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI YAKUHIN KOGYO KK (JP) 2008-09-03 EP disclosed
EP-1400511-B1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI YAKUHIN KOGYO KK (JP) 2008-09-03 EP disclosed
US-6900326-B2 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2005-05-31 US disclosed
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2004-04-01 US disclosed
EP-1400511-A1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI KOGYO CO., LTD. (JP) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827603-B2 Method for preparing 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine and 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine AP2A1, TERT, APEH ITGB3 3715/4885ITGA2B 3610/4885SMYD3 905/4885
US-20220388959-A1 METHOD FOR PRODUCING 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4- MESYLOXYPIPERIDINE AND 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE TERT, APEH, AP2A1 ITGB3 3563/4885ITGA2B 3585/4885SMYD3 1126/4885
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound ORMDL3, MRPS18A, ACSL3 ITGB3 2625/4885ITGA2B 2970/4885SMYD3 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.